NeuCyte

NeuCyte is an early-stage biotechnology company that aims to transform the drug discovery process by utilizing cell-based target-identification and drug-discovery platforms. The company's unique human neural platform, SynFire® iP, allows for the evaluation of human-specific neural phenotypes that are not identifiable in traditional animal models, providing a more reliable predictor of drug efficacy and potential neurotoxicity. With a focus on addressing the unmet needs of patients with neurological disorders, NeuCyte has garnered substantial attention in the Biotechnology, Health Care, and Pharmaceutical industries. Founded in 2015, NeuCyte has recently received a significant $6.70M Series A investment on May 8, 2018, with funding from prominent investors including Cowin Venture and Leaguer Venture Capital. The company's high-caliber team, including top stem cell biologists and neuroscientists, provides NeuCyte with an unrivaled competitive advantage in the market. With its innovative technology and strong backing, NeuCyte is poised to make a significant impact on CNS drug discovery, potentially reducing the high attrition rates of novel drugs in clinical trials and improving patient outcomes in the field of neuroscience.